Coblopasvir (KW136, KW-136) is a novel and potent antiviral agent acting as an HCV NS5A inhibitor. It is a drug candidate being developed in Phase 3 Clinical trials for treatment of HCV infection.

纯度：≥98%

CAS：1312608-46-0